Current Edition

Empowering Real-world Evidence Analysis Through Riskbased De-identification

Clinical trials produce vast amounts of incredibly valuable data that, outside the initial research objectives, is not being sufficiently leveraged, according to Pamela Neely Buffone, Director of Product Management for Privacy Analytics. We are just starting to see the wealth of patient-level data delivering ground-breaking insights – particularly from realworld evidence (RWE) analysis. For years, companies have used real-world data (RWD) to conduct ongoing pharmacovigilance and run comparative analyses of their products. RWE is becoming a valuable tool for decision-making at multiple stages of the drug development process.